Literature DB >> 15231522

Sentinel lymph node mapping of the colon and stomach using lymphoseek in a pig model.

Scott J Ellner1, Jeanette Méndez, David R Vera, Carl K Hoh, William L Ashburn, Anne M Wallace.   

Abstract

BACKGROUND: Lymphoseek is a radiopharmaceutical designed for sentinel lymph node (SLN) mapping. The purpose of this study was to compare Lymphoseek colon and gastric pharmacokinetics with filtered [(99m)Tc]sulfur colloid (fTcSC).
METHODS: Eight anesthetized pigs received an endoscopic injection of Lymphoseek or fTcSC in the stomach and colon. Scintigraphy was obtained of both administration sites at 15-minute intervals up to 3 hours after injection, after which all SLNs were identified by a handheld gamma probe through a laparotomy incision. Isosulfan blue was administered at the injection site 5 minutes before SLN mapping. The percentage of injected dose (%ID) was measured for all harvested nodes, and the clearance half-life (T(c)) was calculated for all injection sites.
RESULTS: The mean Lymphoseek clearance for colon (T(c), 2.56 +/- 1.04 hours) and gastric (T(c), 3.83 +/- 1.18 hours) injection sites was statistically faster (P =.030) compared with fTcSC (colon T(c), 14.98 +/- 3.41 hours; stomach T(c), 14.52 +/- 4.08 hours). After 3 hours, Lymphoseek exhibited a mean SLN %ID of 1.32% +/- 1.71% in the colon and 2.04% +/- 2.12% in the stomach; this was not statistically different from fTcSC (colon,.63% +/-.39%; stomach, 2.35% +/- 2.90%). SLN uptake of Lymphoseek was significantly different from second-echelon node %ID for the colon (P =.011) and gastric (P =.029) injection sites. All SLNs exceeded 10 times background, and there was no discordance between isosulfan blue and Lymphoseek or fTcSC.
CONCLUSIONS: Three hours after colon stomach administration, Lymphoseek demonstrated rapid injection site clearance, detectable SLN uptake, and low second-echelon node uptake.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231522     DOI: 10.1245/ASO.2004.06.007

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek.

Authors:  Anne M Wallace; Carl K Hoh; Denise D Darrah; Gery Schulteis; David R Vera
Journal:  Nucl Med Biol       Date:  2007-08-09       Impact factor: 2.408

2.  A phase 2 study of (99m)Tc-tilmanocept in the detection of sentinel lymph nodes in melanoma and breast cancer.

Authors:  Stanley P L Leong; Julian Kim; Merrick Ross; Mark Faries; Charles R Scoggins; Wendy L Rich Metz; Frederick O Cope; Richard C Orahood
Journal:  Ann Surg Oncol       Date:  2011-02-18       Impact factor: 5.344

3.  γ-Tilmanocept, a New Radiopharmaceutical Tracer for Cancer Sentinel Lymph Nodes, Binds to the Mannose Receptor (CD206).

Authors:  Abul K Azad; Murugesan V S Rajaram; Wendy L Metz; Frederick O Cope; Michael S Blue; David R Vera; Larry S Schlesinger
Journal:  J Immunol       Date:  2015-07-22       Impact factor: 5.422

4.  A receptor-targeted fluorescent radiopharmaceutical for multireporter sentinel lymph node imaging.

Authors:  Derek K Emerson; Karl K Limmer; David J Hall; Sung-Ho Han; William C Eckelman; Christopher J Kane; Anne M Wallace; David R Vera
Journal:  Radiology       Date:  2012-07-02       Impact factor: 11.105

5.  Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a "2-day" protocol.

Authors:  Anne M Wallace; Carl K Hoh; Karl K Limmer; Denise D Darrah; Gery Schulteis; David R Vera
Journal:  Nucl Med Biol       Date:  2009-08       Impact factor: 2.408

Review 6.  Advances in swine biomedical model genomics.

Authors:  Joan K Lunney
Journal:  Int J Biol Sci       Date:  2007-02-10       Impact factor: 6.580

7.  miR-146a-5p inhibits TNF-α-induced adipogenesis via targeting insulin receptor in primary porcine adipocytes.

Authors:  Di Wu; Qian-Yun Xi; Xiao Cheng; Tao Dong; Xiao-Tong Zhu; Gang Shu; Li-Na Wang; Qing-Yan Jiang; Yong-Liang Zhang
Journal:  J Lipid Res       Date:  2016-06-20       Impact factor: 5.922

Review 8.  Carbohydrate-based drugs launched during 2000-2021.

Authors:  Xin Cao; Xiaojing Du; Heng Jiao; Quanlin An; Ruoxue Chen; Pengfei Fang; Jing Wang; Biao Yu
Journal:  Acta Pharm Sin B       Date:  2022-05-23       Impact factor: 14.903

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.